On November 13, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment after radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC) who are ineligible for or who have refused cisplatin based chemotherapy.Full prescribing information for Imfinzi will be posted on Drugs@FDA.Efficacy and SafetyEfficacy

Ori Biotech, a cell and gene therapy manufacturing technology company, has partnered with Europlaz Technologies , a UK-based contract manufacturer of bioprocessing tools and equipment, to support production of consumables for Ori’s IRO platform. The partnership is intended to establish a scalable supply infrastructure for the company’s GMP-ready consumables as demand grows among cell therapy developers, contract development and manufacturing organizations (CDMOs), and academic medical centers. O

iStock, z_wei Cellectis’ business transformation could cost around 160 global employees their jobs. The company has stopped enrollment in its two CAR T programs as it focuses on trials of its in vivo candidates. Two months after announcing it would shift away from allogeneic CAR T cell therapies to focus on in vivo therapies, Cellectis has disclosed that the move will likely trigger a global headcount reduction of up to 70%. The biotech had 229 full-time employees as of Dec. 31, 2025, meaning

LUND, SE / ACCESS Newswire / November 13, 2026 / SynAct Pharma AB (publ) ("SynAct") (STO:SYNACT), ("SynAct"), a clinical-stage biotechnology company focused on treating inflammation, today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance regarding U.S. patent application No. 18/065,702, relating to the immediate-release solid oral dosage formulation of resomelagon (AP1189 acetate) in clinical testing. The Notice of Allowance concludes the e

.HEAL-101 achieved up to 70% in vivo APOC3 editing with liver-restricted activity and confirmed 76% triglyceride reduction in murine models (ESGCT 2026); Phase 1 IIT in China on track for initiation, with preliminary clinical data expected in H2 2027 .HEAL-201 achieved >90% reduction in plasma PCSK9 in a humanized liver mouse model; preliminary clinical data expected in H1 2028 Cash, cash equivalents and fixed-term deposits of $149 million as of September 30, 20261; realignment of the operating

Dengue fever is spread by infected mosquito bites, with Colombia being one of the worst affected countries by the illness. Credit: Pexels Haleon’s LATAM President Andrés González says the Fever Forecaster AI tool combines data, technology and health education to support dengue prevention Dengue is one of the world’s most pressing public health challenges. According to the World Health Organisation (WHO), around half of the global population is now at risk, with an estimated 100-400 million infec

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the pricing of an underwritten offering of 1,894,540 shares of its common stock at an offering price of $31.67 per share. The gross proceeds to Surrozen from the offering, be

More than 500 leaders gathered in New Haven for discussions spanning artificial intelligence, emerging therapies, and investment in oncology NEW HAVEN, Conn.--(BUSINESS WIRE)--On November 9–10, the inaugural Future of Oncology Summit brought together over 500 leaders from academia, biotechnology, pharmaceuticals, investment, and the broader oncology ecosystem at 101 College Street in New Haven. The two-day event featured more than 70 speakers, including keynote speakers Clifford Hudis, MD, CEO o

Company plans to Earnings Report on November 16, 2026 on Form 10-Q for the quarter ended September 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / November 13, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX ) today announced that the company will conduct an investor webcast on Tuesday, November 17, 2026 at 8:30 a.m. Eastern to review third-quarter 2026 financials and provide corporate updates. Participation Instructions for Jaguar Health Investor Webcast When: Tuesday, November 17, 2026 at 8:30 a.m

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares